Core Insights - Candel Therapeutics is set to present three key studies at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, highlighting its advancements in cancer immunotherapy [1][2][3] Company Developments - Candel's presentations will showcase its leadership in developing novel therapeutics that utilize multi-omics insights and artificial intelligence to enhance understanding of tumor microenvironments and biomarkers [2][3] - The company plans to submit a Biologics License Application (BLA) for its lead product candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in Q4 2026 [4][8] Clinical Trial Results - Positive phase 3 clinical trial data for CAN-2409 in localized prostate cancer will be presented, achieving its primary endpoint and supported by secondary endpoints [4][8] - A phase 2a open-label clinical trial of CAN-2409 in patients with stage III/IV non-small cell lung cancer (NSCLC) will also be discussed, integrating over 3,000 data points to understand clinical and biological responses [6][9] Key Findings - In the NSCLC trial, patients with non-squamous histology showed greater immune response and improved survival compared to those with squamous histology, supporting further investigation in this subgroup [7][14] - The enLIGHTEN™ Discovery Platform demonstrated a 60% tumor growth suppression in preclinical models, indicating its potential for precision immunotherapy design [10][15] Product Information - CAN-2409 is an investigational, off-the-shelf biological immunotherapy designed to induce a systemic anti-tumor immune response, with over 1,000 patients dosed in clinical trials showing a favorable tolerability profile [12][16] - The enLIGHTEN™ Discovery Platform aims to create new multimodal biological immunotherapies by leveraging human biology and advanced analytics [18]